Both approved Fabry ERTs are already NPHC-covered in the GCC, so the opening is the 30 to 50 patient ADA-positive cohort no one serves.

Unusually for GCC rare disease, both agalsidase beta (Fabrazyme) and agalsidase alfa (Replagal) are SFDA-registered and NPHC-covered, a broader ERT choice than the US market, where only agalsidase beta is FDA-approved. Migalastat (Galafold) is also SFDA-registered, but its HEK amenable-mutation assay is contracted exclusively to KFSH&RC in Saudi Arabia, meaning Fabry patients outside that single centre cannot access oral therapy even when their mutation would otherwise qualify. Pegunigalsidase alfa (Elfabrio), FDA- and EMA-approved in 2023, has not been filed for SFDA registration since Chiesi has not prioritised the GCC market, leaving an estimated 30-50 GCC patients with high antibody titres and suboptimal ERT response with no ADA-targeted option.

Female symptomatic Fabry heterozygotes are a second, GCC-specific underserved segment: an estimated 40% of GCC-treated Fabry patients are symptomatic females, yet 50-60% of eligible female heterozygotes remain untreated because they present to general internal medicine rather than metabolic specialists, and physician perception often incorrectly treats female disease as milder. Large Gulf Arab family sizes, five to eight children on average, mean each identified index case generates more at-risk relatives through cascade screening than in smaller Western families, making family-cascade identification a structurally stronger tool in GCC than elsewhere.

Access is already solved here; the gap is one specific unaddressed cohort.

Five questions this report answers:

Q1 - What must a new Fabry agent prove in a market with two ERTs and an oral chaperone already covered?

Q2 - How large is the ADA-positive and female-heterozygote underserved population, and how is it identified?

Q3 - What NPHC and KFSH&RC groundwork needs to start before launch?

Q4 - What determines whether a pre-launch Fabry disease agent succeeds commercially in the GCC?

Q5 - What deliverables and sourcing standard back every AXLRx GCC Fabry assessment?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#FabryDisease #GCC #SFDA #NPHC #RareDisease #LaunchReadiness

Live report page:  https://axlrx.ai/fabry-disease/gcc/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/